Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Whooping cough persistence traced to key toxin

20.12.2005


A key toxin associated with whooping cough helps the germs resist the human immune system and infect vaccinated populations. Discovery of this resistance mechanism could lead to potential new treatments for the disease, according to researchers at Penn State.



Whooping cough, or pertussis, is a highly contagious respiratory disease caused by the germ Bordetella pertussis. Whooping cough can occur at any age but is generally considered a childhood disease marked by severe spells of coughing and a characteristic whooping sound while inhaling. Though the widespread use of vaccines has helped reduce disease drastically, recent surveys reveal that the disease is increasingly being diagnosed in a large number of vaccinated adults, posing a serious health risk to unvaccinated children and infants.

"One of the great mysteries of pertussis is how it persists within populations despite high vaccination rates," says Eric Harvill, assistant professor of microbiology and infectious disease in the College of Agricultural Sciences.


Tests on infected mice show that serum antibodies are usually able to clear the germ from the lungs by recruiting large numbers of neutrophils, a type of white blood cells that kill germ cells, by surrounding and absorbing them. But while the technique is successful against B. bronchiseptica – a closely related germ that causes kennel cough in dogs – within a day, it takes longer to clear B. pertussis.

Antibodies produced by the vaccines are effective only seven days after they are administered, says Harvill, who is part of Penn State’s Center for Infectious Disease Dynamics. "The bacterium appears to have a mechanism to resist the effects of antibodies during the first week of infection," he adds.

Harvill’s group theorized that one or more genes specific to pertussis were somehow delaying the effectiveness of the vaccine. They looked specifically at the genes encoding Pertussis toxin, PTx, and hypothesized that this toxin somehow interfered with antibody-mediated bacterial clearance.

To test their theory that those pertussis germs without the toxin would be more susceptible to antibodies, Harvill and his colleagues inoculated one set of mice with genetically engineered B. pertussis that lacked the toxin, and another set with the naturally occurring strain. Both strains grew well in these mice, but when antibodies that recognize B. pertussis were given to each group they rapidly eliminated only the strain lacking the toxin.

Further tests suggest that the toxin acts directly on white blood cells to temporarily prevent their movement across tissues that line various organs.

"This is a particular strategy by B. pertussis," says Harvill, whose findings are published in the current (December) issue of Journal of Clinical Investigation.

The Penn State researcher says the mechanism for preventing the migration of white blood cells is a key adaptation by B. pertussis to prolong the infection period in immune and vaccinated hosts.

"B. pertussis effectively avoids the immune system during the first week of infection, giving it enough time to successfully grow, and potentially spread to more people," explains Harvill.

Acute infections are like forest fires, says Ottar Bjornstad, associate professor of entomology and biology at Penn State and a co-author of the study. He notes, "And while highly infectious pathogens will spread rapidly, they may burn through the susceptible population so quickly that they run the risk of extinction."

"Pertussis cleverly avoids this by using a toxin to allow re-infecting of those who have been vaccinated or infected earlier," adds Bjornstad, also co-director of the Center for Infectious Disease Dynamics.

According to Harvill, the new understanding could lead to potential new treatments for whooping cough.

"The most direct treatment could involve inactivating the toxin, or simply having vaccines that produce more antibodies specific to the toxin," notes the Penn State researcher.

Amitabh Avasthi | EurekAlert!
Further information:
http://www.psu.edu

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>